{"title":"人工智能驱动的 CRISPR-Cas9 基因组编辑在增强 CAR T 细胞疗法方面的变革潜力","authors":"","doi":"10.1016/j.compbiomed.2024.109137","DOIUrl":null,"url":null,"abstract":"<div><p>This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes.</p></div>","PeriodicalId":10578,"journal":{"name":"Computers in biology and medicine","volume":null,"pages":null},"PeriodicalIF":7.0000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0010482524012228/pdfft?md5=9e5091baed3a845f17da4f6e8d1805c6&pid=1-s2.0-S0010482524012228-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy\",\"authors\":\"\",\"doi\":\"10.1016/j.compbiomed.2024.109137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes.</p></div>\",\"PeriodicalId\":10578,\"journal\":{\"name\":\"Computers in biology and medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0010482524012228/pdfft?md5=9e5091baed3a845f17da4f6e8d1805c6&pid=1-s2.0-S0010482524012228-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Computers in biology and medicine\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0010482524012228\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Computers in biology and medicine","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0010482524012228","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
这篇叙述性综述探讨了将人工智能(AI)与 CRISPR-Cas9 基因组编辑技术相结合以推进 CAR T 细胞疗法的巨大潜力。人工智能算法在识别基因靶点方面具有无与伦比的精确性,这对提高 CAR T 细胞疗法的疗效至关重要。这种精确性对于消除有损治疗效果的负面调节因素至关重要。此外,人工智能简化了生产流程,大大降低了成本,提高了可及性,从而鼓励了进一步的研发投资。人工智能集成的一个关键优势是提高了安全性;通过预测和最大限度地减少脱靶效应,人工智能增强了 CRISPR-Cas9 编辑的特异性,有助于提高 CAR T 细胞疗法的安全性。这一进步对患者安全和更广泛的临床应用至关重要。人工智能和 CRISPR-Cas9 的融合具有变革潜力,有望彻底改变个性化免疫疗法。这些创新可以将 CAR T 细胞疗法的应用范围从血液系统恶性肿瘤扩展到各种实体瘤和其他非血液系统疾病,从而预示着一个能大幅改善患者预后的癌症治疗新时代的到来。
The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy
This narrative review examines the promising potential of integrating artificial intelligence (AI) with CRISPR-Cas9 genome editing to advance CAR T-cell therapy. AI algorithms offer unparalleled precision in identifying genetic targets, essential for enhancing the therapeutic efficacy of CAR T-cell treatments. This precision is critical for eliminating negative regulatory elements that undermine therapy effectiveness. Additionally, AI streamlines the manufacturing process, significantly reducing costs and increasing accessibility, thereby encouraging further research and development investment. A key benefit of AI integration is improved safety; by predicting and minimizing off-target effects, AI enhances the specificity of CRISPR-Cas9 edits, contributing to safer CAR T-cell therapy. This advancement is crucial for patient safety and broader clinical adoption. The convergence of AI and CRISPR-Cas9 has transformative potential, poised to revolutionize personalized immunotherapy. These innovations could expand the application of CAR T-cell therapy beyond hematologic malignancies to various solid tumors and other non-hematologic conditions, heralding a new era in cancer treatment that substantially improves patient outcomes.
期刊介绍:
Computers in Biology and Medicine is an international forum for sharing groundbreaking advancements in the use of computers in bioscience and medicine. This journal serves as a medium for communicating essential research, instruction, ideas, and information regarding the rapidly evolving field of computer applications in these domains. By encouraging the exchange of knowledge, we aim to facilitate progress and innovation in the utilization of computers in biology and medicine.